PD-1

Introduction

Programmed cell death 1 (PD-1) is a costimulatory molecule belonging to the CD28/CTLA-4 family. PD-1 recruits and activates an activation signaling pathway such as protein tyrosine phosphatase by binding to programmed cell death ligand 1 or 2 (PD-L1 or PD-L2). Abnormal PD-1/PD-L signaling can cause the immune microenvironment in the body to lose its steady state, leading to autoimmune diseases or tumors. PD-1 is an important factor in maintaining self-tolerance. Under physiological conditions, PD-1 recognizes antigen through T cell receptor TCR (T cell receptor), regulates the function of T cells in peripheral tissues, and regulates the body’s foreign or autoantigen. An immune response that prevents the development of immune-related diseases. PD-1/PD-L1 immune checkpoint inhibitors are different from traditional tumor treatments, but use the body’s own immune system to play a role in killing tumors. It has demonstrated excellent efficacy in a variety of solid tumors and hematological malignancies. Its greatest advantage is its long-lasting response and long-term survival.

Figure 1 Mechanisms of programmed cell death protein 1 (PD1) signalling in T cells. ( Sharpe et al 2017)

PD-1 / PD-L1 signaling pathway

There are two ligands for PD-1, PD-L1 (B7-H1/CD273) and PD-L2 (B7-DC/CD274), which have similar effects. The main functions are combined with PD-1. Inhibition of T cell receptor-mediated B cell proliferation and production of interleukin 2, 10, interferon gamma and other cytokines leads to cell cycle arrest, thereby inhibiting T cell activation. Because PD-L1 is the main component of these two PD-1 ligands, the current research on PD-1 ligands is mainly focused on PD-L1. PD-1 on the surface of activated T lymphocytes can specifically recognize PD-L on antigen-presenting cells (APC), thereby activating PD-1/PD-L pathway, thereby attenuating the effects of Ras-MAPK and other pathways. It then leads to a decrease in the expression of three transcription factors, AP-1, NF-AT and NF-κB, thereby inhibiting T cell proliferation, differentiation and secretion of cytokines.

PD-1 and diseases

The expression of PD-1 is associated with the development and progression of various autoimmune diseases. Studies have shown that PD-1 knockout mice can elicit multiple autoimmune diseases. For example, PD-1 knockout mice with a C57BL/6 gene background develop lupus-like glomerulonephritis and lethal dilated cardiomyopathy. The PD-1 signaling pathway is also involved in the progression of viral and microbial infectious diseases. Virus-specific cytotoxic T cells (CTLs) were found to be PD-1 positive in LCMV-infected mice, whereas this group was not found in the acute infection model. These PD-1 positive failing CTLs were found in patients with chronic HIV, HCV, and HBV infection. In addition, PD-1 expression was positively correlated with viral load.

Anti-PD-1 drug and its clinical application

(1) Nivolumab (Opdivo). The antibody type is fully human IgG4, which restores the immune effect of T lymphocytes during anti-tumor therapy. For the treatment of liver cancer, treatment of gastric cancer, metastatic non-small cell lung cancer, etc.

(2) Pembrolizumab (Keytruda). The antibody type is humanized IgG4, the first anti-PD-1 monoclonal antibody marketed in the United States.

(3) Pidilizumab. It is an anti-PD-1 humanized IgG-1κ monoclonal antibody, which is indicated for the treatment of melanoma and recurrent follicular lymphoma.

(4) AMP-224. The antibody type is PD-L2 IgG2a fusion protein for the treatment of advanced solid tumors. Clinical treatment has an infusion reaction and no drug-related inflammatory adverse reactions.

References

  1. Longo, D. L. , & Boussiotis, V. A. . (2016). Molecular and biochemical aspects of the pd-1 checkpoint pathway. New England Journal of Medicine, 375(18), 1767-1778.
  2. Liu, J. , Zhang, S. , Hu, Y. , Yang, Z. , & Lu, X. . (2016). Targeting pd-1 and tim-3 pathways to reverse cd8 t-cell exhaustion and enhance ex vivo t-cell responses to autologous dendritic/tumor vaccines. Journla of Immunotherapy, 39(4), 171-180.
  3. Sharpe, A. H. , & Pauken, K. E. . (2017). The diverse functions of the pd1 inhibitory pathway. Nature Reviews Immunology.